2016. 11 4 different novel humanized antibodies patents application

2016. 12 Nomination of the family company of KRIBB

2016. 12 Confirmation of Rheumatoid arthritis efficacy of Immune modulating Ab in CIA monkey model

2017. 08 Strategic alliance with Shanghai OPM Biosciences Co., Ltd. of China

2018. 02 400 billion won-size Licensing Deal with Aprogen KIC. 4 programs (DNP001, DNP004, PD-1 Ab. And CD47 Ab.) were licensed-out

2018. 05 Listing on KONEX (Korea New Exchange) market

2018. 10 Nomination as a new candidate (H2319, DNP002) on National Onco-Venture (NOV)

2019. 03 Research collaboration agreement with EpimAb Biotherapeutics in China on development of bispecific antibody candidates

2019. 06 Research collaboration agreement with Harbour BioMed in China on development of fully antibody candidates

2014. 03 Contract of organizer change to Korea Investment Co., Ltd.

2014. 05 Clinical phase 1 examination initiation (ASAN Medical Center)

2014. 07 Licensing agreement with China 3S bio company

2014. 09 KDDF leukemia therapeutic antibody clinical phase 1 selected (4 billion won)

2014. 09 Head office and lab moved to ASAN Medical Center Asan institute for life sciences

2015. 05 Immune regulation antibody primates 6 months ADA suppress result secured

2015. 06 Subject of breast cancer antibody drug of future industry led by technology development work selected (2.2 billion won)

2015. 07 Thesis of lung cancer antibody drug published

2012. 02 Medical device approved by China’s food and drug organization

2012. 06 Monkey experiment of homogeneous organ transplant (Islet) and homogeneous organ transplant (kidney) initiation

2013. 02 Non-clinical subject of KDDF homogeneous islet transplant selected (4.4 billion won)

2013. 06 Completion of non-clinical antibody treatment of leukemia

2013. 12 Immune regulation antibody & Leukemia therapeutic antibody patent

2013. 12 Ministry of Health and Welfare level 2 Bio xeno-transplantation development agency xeno-islet transplantation subject selected (Seoul National University 2.2 billion won)

2013. 12 Leukemia therapeutic antibody clinical phase 1 IND approved (Korean Food and Drugs Administration

2007. 05 Transfer of medical device business agreement with TNL Inc.

2007. 05 Establishment of laser medical device department

2009. 10 Progress of leukemia therapeutic antibody preclinical trials

2011. 01 Sixth progress of immune regulation antibody animal (monkey) testing

2011. 10 Journal of Experimental Medicine (U.S Experimental medicine journal) thesis published and press release of immune suppression antibody

2011. 10 Immune regulation antibody (MD-3) technology transfer agreement with Seoul National University R&D foundation

1999. 02 Foundation of DiNonA Inc.

1999. 08 Confirmation of venture business

2001. 04 Foundation of company affiliated lab

2001. 08 Selected as INNO-BIZ company

2003. 07 Establishment of diagnostic reagent department

2005. 08 Transfer of technology agreement about acute leukemia with Seoul National University R&D foundation

2005. 09 License agreement about acute leukemia with the Arana (U.S and Australia)

2005. 11 License agreement about acute leukemia with Kwang Dong Pharmaceutical Co., Ltd.